High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial
Jeroen van Dorp(The Netherlands Cancer Institute), Christodoulos Pipinikas, Britt B.M. Suelmann(University Medical Center Utrecht), Niven Mehra(Radboud University Nijmegen), Nick van Dijk(The Netherlands Cancer Institute), Giovanni Marsico, Maurits L. van Montfoort(The Netherlands Cancer Institute), Sophie Hackinger, Linde M. Braaf(The Netherlands Cancer Institute), Tauanne Amarante, Charlaine van Steenis(The Netherlands Cancer Institute), Kirsten McLay, Antonios Daletzakis(The Netherlands Cancer Institute), Daan van den Broek(The Netherlands Cancer Institute), Maaike W. van de Kamp(The Netherlands Cancer Institute), Kees Hendricksen(The Netherlands Cancer Institute), Jeantine M. de Feijter(The Netherlands Cancer Institute), Thierry N. Boellaard(The Netherlands Cancer Institute), Richard P. Meijer(University Medical Center Utrecht), Antoine G. van der Heijden(Radboud University Nijmegen), Nitzan Rosenfeld(Cancer Research UK Cambridge Center), Bas W.G. van Rhijn(The Netherlands Cancer Institute), Greg Jones(Babraham Institute), Michiel S. van der Heijden(The Netherlands Cancer Institute)
Cited by 76Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis